Theranostics 2017; 7(16):3933-3947. doi:10.7150/thno.21529
Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease
1. Centre for Comparative Genomics, Murdoch University, Murdoch, Perth, Australia 6150;
2. Perron Institute for Neurological and Translational Science, QEII Medical Centre, Nedlands, Perth, Australia 6005;
3. School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, Australia 4072.
Nucleic acid-based technologies have received significant interest in recent years as novel theranostic strategies for various diseases. The approval by the United States Food and Drug Administration (FDA) of Nusinersen, an antisense oligonucleotide drug, for the treatment of spinal muscular dystrophy highlights the potential of nucleic acids to treat neurological diseases, including Alzheimer's disease (AD). AD is a devastating neurodegenerative disease characterized by progressive impairment of cognitive function and behavior. It is the most common form of dementia; it affects more than 20% of people over 65 years of age and leads to death 7-15 years after diagnosis. Intervention with novel agents addressing the underlying molecular causes is critical. Here we provide a comprehensive review on recent developments in nucleic acid-based theranostic strategies to diagnose and treat AD.
Keywords: nucleic acids, Alzheimer's disease, amyloid beta peptides, tau peptide, chemically modified oligonucleotides, nucleic acid therapeutics.
Chakravarthy M, Chen S, Dodd PR, Veedu RN. Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease. Theranostics 2017; 7(16):3933-3947. doi:10.7150/thno.21529. Available from http://www.thno.org/v07p3933.htm